Pietro Rosellini

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

Karin Hardt, An Vandebosch, Jerald Sadoff et al. · The Lancet Infectious Diseases · 2022 · 88 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer

Pietro Rosellini, Samuel Amintas, Charline Caumont et al. · European Journal of Cancer · 2022 · 45 citations

Medicine, Molecular Genetics, Oncology +11

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Edoardo Francini, Francesca Montagnani, Pier Vitale Nuzzo et al. · JAMA Network Open · 2021 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17

Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer

Giandomenico Roviello, Roberto Petrioli, Valerio Nardone et al. · Medicine · 2018 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective

Andrea Spini, Rosa Gini, Pietro Rosellini et al. · Cancers · 2021 · 12 citations · Full text

Medicine, Oncology, Pharmacotherapy +15